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Ataxia-telangiectasia at the crossroads
ATM, the gene product mutated in the cancer susceptibility syndrome
ataxia-telangiectasia, is related to proteins involved in DNA repair and
cell-cycle control, perhaps explaining how ATM prevents carcinogenesis.
Ataxia-telangiectasia (AT) is a human autosomal recessive
disorder characterized by a plethora of debilitating symp-
toms. These include unsteady posture (ataxia), dilated
blood vessels (telangiectasia), growth retardation, pro-
gressive neurological degeneration, immune deficiencies,
premature ageing and an approximately 100-fold
increased incidence of cancer (see [1] and references
therein). Although individuals homozygous for AT-caus-
ing mutations are relatively rare (approximately 1 in
50 000 of the general population), heterozygotes, com-
prising around 1% of the population, also have signi-
ficantly enhanced tumour incidence [2]. Indeed, up to
9 % of breast cancer patients may be heterozygous for
AT-causing mutations.
At the cellular level, AT is characterized by a high degree
of chromosomal instability and hypersensitivity to agents
that cause DNA-strand breaks, including ionizing radia-
tion and restriction endonucleases [3]; cells heterozygous
for an AT-causing mutation show intermediate sensitivity
to these agents. This suggests that AT cells are defective
in the repair or recognition of DNA damage. Consistent
with this suggestion, AT cells are deficient in radiation-
induced cell-cycle checkpoint controls, which arrest the
cell cycle in response to radiation in order to allow any
necessary repairs to be carried out before division. After
irradiation, normal cells arrest at the G1-S, S or G2-M
phases of the cell cycle. The G1-S- and S-phase check-
points ensure that damaged DNA is not replicated: oth-
erwise, this would result in genomic instability or in
mutations becoming 'fixed' in the next generation. The
G2-M-phase checkpoint prevents cell division until
lesions in the DNA - particularly DNA double-strand
breaks - have been repaired. AT cells are impaired in
each of the above checkpoints, suggesting that the AT
gene product functions in a signalling pathway that
recognizes DNA damage and transduces the signal from
the damaged DNA to the cell-cycle machinery.
Recently, a gene termed ATM (AT-mutated) has been
identified; it is debilitated in all individuals with AT so
far analyzed, and it maps to the genomic locus that com-
plements the AT phenotype [4]. ATM encodes a large
polypeptide, the carboxy-terminal 400 amino-acid resi-
dues of which are homologous to the catalytic domains
of members of the phosphatidyl inositol (PI) 3-kinase
family [5]. Phylogenetic analyses (Fig. 1) reveal that the
ATM protein is most closely related to several very large
proteins that define a subgroup of the PI 3-kinase family.
These include the Schizosaccharomyces pombe Rad3 protein
and its probable Saccharomyces cerevisiae homologue,
Meclp/Esrlp. Strikingly, rad3 or mecl mutants are defec-
tive in meiosis, are sensitive to ionizing radiation and
ultraviolet light, and lack the checkpoint mechanism
which ensures that mitosis is dependent on the com-
pletion of DNA replication (see [1,6] and references
therein). A putative Drosophila homologue of rad3 and
MEC1 has been identified recently as the mei-41 gene
[7]. Mutations in this gene result in reduced rates of
meiotic recombination, and mei-41 cells are sensitive to
DNA-damaging agents, are unable to delay mitosis in
response to DNA damage, and have elevated genomic
instability. Most closely related to ATM, however, is
S. cerevisiae Tellp [8,9]. Notably, tell mutant strains have
shortened telomeres, along with heightened levels of
mitotic recombination and chromosome loss. Such
strains are viable, have no detectable checkpoint defects,
and are not hypersensitive to radiation, but tell mutations
Fig. 1. Relationship of ATM to other members of the PI 3-kinase
family. The protein sequence alignment, performed as described
in [6], was used to construct a phylogenetic tree using the
ClustalW and PHYLIP package. Blue highlighting indicates the
group of large (> 270 kDa) proteins that comprise the DNA-
PKs/ATM subgroup of the PI 3-kinase family; yellow indicates
the subgroup that includes PI 3-kinase itself. The proteins shown
are: DNA-PKCs, FRAP (human FRAP), TOR1 (Saccharomyces
cerevisiae Torlp), ATM, TELl (S. cerevisiae Tellp), RAD3(Schizosaccharomyces pombe Rad3), MEI-41 (Drosophila Mei-
41), MEC1 (S. cerevisiae Mecld p/Esr1 p), p110 (the 110 kDa cat-
alytic subunit of mammalian PI 3-kinase), VPS34 (S. cerevisiae
VPS34), PIK1 (S. cerevisiae PIK1).
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Fig. 2. Possible mechanisms of ATM
function. A DNA-damage sensor could
interact with ATM directly (single
arrow), or indirectly (multiple arrows)
via other proteins or through a
signalling pathway. ATM could then
function in several ways. One is to trig-
ger a phosphatidyl inositol phosphate
(PIP) signalling pathway; another is,
either directly or indirectly, to activate
transcription factors such as p53 and
NF-KB. If ATM is part of a protein com-
plex that senses DNA damage, it could
also function more directly in DNA
repair by activating or recruiting com-
ponents of the DNA-repair machinery to
site of DNA damage.
do enhance the radiosensitivity of mecl- strains.
Furthermore, TEL1 over-expression complements the
phenotype of a strain expressing a truncated derivative of
Meclp [9]. Together, these data imply that Meclp and
Tellp function in distinct but overlapping pathways for
sensing and/or responding to DNA damage, and suggest
that they function analogously to ATM. Other proteins
in the ATM family are S. cerevisiae Torlp and Tor2p and
their mammalian counterpart FRAP, which function, at
least in part, by controlling progression through the G1
phase of the cell cycle (for example, see [10]).
How might ATM function at the molecular level?
Potential answers have recently been suggested by studies
of the enzyme DNA-dependent protein kinase (DNA-
PK), a nuclear protein-serine/threonine kinase that phos-
phorylates DNA-bound substrates [11]. DNA-PK has
two components - one mediates DNA binding and
corresponds to the human autoimmune disease antigen
Ku; the other is the DNA-PK catalytic subunit (DNA-
PKCs), which is activated upon association with DNA-
bound Ku. DNA-PKcs is a polypeptide of around
460 kDa, the carboxy-terminal domain of which falls
into the ATM subgroup of the PI 3-kinase family (Fig. 1)
[6]. Notably, DNA-PK is active only when bound to the
ends of DNA or other discontinuities in the DNA dou-
ble helix. Cell lines defective in DNA-PK are deficient in
joining DNA double-strand breaks, are hypersensitive to
ionizing radiation, and display defects in V(D)J recombi-
nation - the site specific recombination process that
assembles mature immunoglobulin and T-cell receptor
genes in developing lymphocytes [11]. DNA-PK there-
fore appears to be a component of the mammalian
machineries for repairing double-strand breaks and
recombining V(D)J gene segments.
A recurring feature of PI 3-kinase family members is their
association with regulatory subunits. For example, DNA-
PKcs is targeted to DNA double-strand breaks by Ku [11],
and mammalian PI 3-kinase is linked to activated growth
factor receptors by its associated 85 kDa subunit [5]. It is
therefore possible that ATM and its close relatives also
interact with regulatory subunits, and that these subunits
serve to recognize DNA damage and/or partially repli-
cated DNA. Tellp, and perhaps ATM, might also interact
with specific DNA structures occurring in telomeres, as a
mechanism for sensing telomeric length. Shortened telo-
meres are associated with cellular senescence and increased
chromosomal instability; as AT cells have been reported to
have relatively short telomeres, it will be interesting to see
whether this contributes to the premature ageing or
genomic instability phenotypes of the clinical disease.
Because DNA-PK is thought to function in DNA repair
directly [11], it is possible that this is also the case for
ATM. Although there is little direct evidence to support
this proposal, AT cells display higher levels of unrepaired
DNA damage than do normal cells after irradiation, and
AT cells are less precise at repairing DNA double-strand
breaks than are normal cells [3]. Furthermore, repaired
molecules suffer deletions at an unusually high frequency
in AT cells, a situation reminiscent of the large deletions
frequently associated with attempted V(D)J recombina-
tion events in DNA-PK-deficient cells. An involvement
of ATM in V(D)J recombination or immunoglobulin
class-switch recombination could help to explain the
immunological deficiencies seen in AT patients.
Some PI 3-kinase family members phosphorylate inositol
phospholipids that serve as intracellular second mes-
sengers [5]. An attractive hypothesis, therefore, is that
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ATM is also a lipid kinase, and that the phosphorylated
lipids it generates feed into signalling pathways that regu-
late cell-cycle progression or the activity of DNA-repair
components. To date, however, no protein in the ATM
subgroup of the PI 3-kinase family has been shown to
phosphorylate lipids. Instead, protein kinase activities
have been demonstrated for DNA-PK and several other
PI 3-kinase family members, suggesting that ATM may
be a protein kinase. If so, what proteins might ATM
phosphorylate? One possibility is that ATM feeds into a
protein kinase cascade that modulates the activity of the
cell cycle regulatory apparatus (Fig. 2).
An additional potential downstream target for ATM is
the transcription factor NF-KB. In most cells, NF-KB is
normally restrained in the cytoplasm by association with
the inhibitor IKB. In response to various stimuli, how-
ever, including ultraviolet light and ionizing radiation,
IKB becomes phosphorylated in its carboxy-terminal
region and is then degraded, allowing NF-KB to enter
the nucleus and activate transcription. Interestingly,
NF-KB activity is constitutively high in AT cells, and the
radiosensitivity of AT cells is complemented by a trun-
cated IKB that lacks the carboxy-terminal phosphory-
lation sites [12]. These findings suggest that ATM lies on
a signalling pathway that regulates NF-KB activity. As
NF-KB controls the transcription of many genes that play
important roles in the development and function of the
immune system, defects in NF-KB signalling could help
explain the immunological defects of AT patients.
Several lines of evidence suggest that the tumour
suppressor p53 is another downstream target of ATM.
First, patients heterozygous for mutations in the p53
gene are somewhat similar to individuals with AT, in
that they display increased genomic instability and
enhanced tumour incidence. Second, AT cells show
delayed or sub-optimal induction of p53 protein in
response to DNA-damaging agents [13]. As p53 is an
effective substrate for DNA-PK in vitro, this raises the
exciting possibility that ATM targets p53 directly. The
induction of p53 is involved in triggering the G1-S
checkpoint system and the induction of factors that
stimulate DNA repair, so a link between ATM and p53
could potentially explain the cell-cycle checkpoint
defects and genomic instability of AT cells. Furthermore,
possible defects in controlling p53-mediated apoptosis in
AT cells could perhaps explain the reduced stature,
immune system defects, and neurodegeneration pheno-
types of people with AT.
The cloning of the ATM gene has opened up many
exciting avenues for future research. One will be to map
functional domains of ATM, identify interacting factors,
and elucidate its precise biochemical role(s). Another will
be to devise genetic screens to allow the efficient detec-
tion of AT heterozygotes. Once recognized, these indi-
viduals could be advised on how to alter their lifestyles to
minimize tumour risk, and could be monitored to allow
any cancers that arise to be detected in their early, more
easily treatable stages. Finally, it will be of great impor-
tance to establish whether deficiencies in other compo-
nents of the ATM signalling pathway, or in ATM relatives,
are associated with enhanced cancer risk in humans.
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